Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 256

Sort by

Sort Order Select

Journal Articles

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Zhuoer Xie, Jenna Fernandez, Terra Lasho, Christy Finke, Michelle Amundson, Kristen B. McCullough, Betsy R. LaPlant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle Elliott, Thomas E. Witzig, Mrinal M. Patnaik

Blood (2024) 144 (23): 2456–2461.

https://doi.org/10.1182/blood.2024024962

Published: 2024

Includes: Supplemental data

Journal Articles

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Yael Kusne, Talha Badar, Terra L. Lasho, Ludovica Marando, Abhishek A. Mangaonkar, Christy Finke, James M. Foran, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Jeanne Palmer, David Viswanatha, Mark R. Litzow, Timothy Chlon, Alejandro Ferrer, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 440.

https://doi.org/10.1182/blood-2024-203879

Published: 2024

Journal Articles

Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis

Ayalew Tefferi, Chandra Hutchens, Antoine N. Saliba, Giuseppe Gaetano Loscocco, Kebede Begna, William J. Hogan, Kaaren K. Reichard, Animesh D. Pardanani, Sima Bhatt, William Savage, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6678.

https://doi.org/10.1182/blood-2024-209070

Published: 2024

Journal Articles

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Giuseppe Gaetano Loscocco, Moazah Iftikhar, Masooma S Rana, Omer Karrar, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Natasha Szuber, Tiziano Barbui, Paola Guglielmelli, Alessandro Maria Vannucchi, Cinthya Zepeda Mendoza, Kaaren K. Reichard, Rong He, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6621.

https://doi.org/10.1182/blood-2024-193373

Published: 2024

Journal Articles

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Clifford M. Csizmar, Anuya A. Natu, Rashmi Kanagal-Shamanna, Kelly S. Chien, Danielle Hammond, Sanam Loghavi, Alexandre Bazinet, Terra L. Lasho, Christy Finke, Aref Al-Kali, Hassan B Alkhateeb, Naseema Gangat, Abhishek A. Mangaonkar, Antoine N. Saliba, Ayalew Tefferi, Guillermo Garcia-Manero, Hagop Kantarjian, Guillermo Montalban-Bravo, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 6747.

https://doi.org/10.1182/blood-2024-209126

Published: 2024

Journal Articles

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients with Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

Patricia Carey, Animesh D. Pardanani, Patrick Starlinger, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 6662.

https://doi.org/10.1182/blood-2024-199246

Published: 2024

Journal Articles

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Blood (2024) 144 (Supplement 1): 6657.

https://doi.org/10.1182/blood-2024-193917

Published: 2024

Journal Articles

Revised International Working Group Risk Model for Survival in Polycythemia Vera

Ayalew Tefferi, Giuseppe Gaetano Gaetano Loscocco, Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Alessandro Atanasio, Fiorenza Vanderwert, Alessio Enderti, Animesh D. Pardanani, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Paola Guglielmelli, Naseema Gangat, Alessandro Maria Vannucchi

Blood (2024) 144 (Supplement 1): 1785.

https://doi.org/10.1182/blood-2024-193118

Published: 2024

Journal Articles

Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Paola Guglielmelli, Chiara Maccari, Manjola Balliu, Giuseppe Gaetano Loscocco, Naseema Gangat, Alessandro Atanasio, Paolo Cicogna, Leonardo Signori, Giada Rotunno, Niccolò Bartalucci, Gloria Nanni, Anna Catelani, Rossella Manfredini, Chiara Paoli, Ayalew Tefferi, Alessandro Maria Vannucchi

Blood (2024) 144 (Supplement 1): 1795.

https://doi.org/10.1182/blood-2024-198891

Published: 2024

Journal Articles

Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts

Ayalew Tefferi, Giuseppe Gaetano Gaetano Loscocco, Maymona Abdelmagid, Animesh D. Pardanani, Kebede Begna, Mrinal M. Patnaik, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Kaaren K. Reichard, Paola Guglielmelli, Naseema Gangat, Alessandro M. Vannucchi

Blood (2024) 144 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2024-193907

Published: 2024

Journal Articles

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

Maymona Abdelmagid, Jeanne Palmer, Aref Al-Kali, Mehrdad Hefazi, James M. Foran, Kebede Begna, Cecilia Y. Arana Yi, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1798.

https://doi.org/10.1182/blood-2024-198757

Published: 2024

Journal Articles

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

Masooma S Rana, Moazah Iftikhar, Yamna Jadoon, Maymona Abdelmagid, David Viswanatha, Rong He, Kaaren K. Reichard, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 1797.

https://doi.org/10.1182/blood-2024-193119

Published: 2024

Journal Articles

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

Blood (2024) 144 (Supplement 1): 244.

https://doi.org/10.1182/blood-2024-210251

Published: 2024

Journal Articles

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Naseema Gangat, James M. Foran, Anna B. Halpern, Raajit Rampal, Prithviraj Bose, Elizabeth O. Hexner, Moshe Talpaz, Laura C. Michaelis, Prioty Islam, Ronan T. Swords, Sima Bhatt, Akshay Buch, Olivia Pelletier, Will Savage, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 657.

https://doi.org/10.1182/blood-2024-203719

Published: 2024

Journal Articles

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Maymona Abdelmagid, Kaaren K. Reichard, Cinthya Zepeda Mendoza, Animesh D. Pardanani, Ayalew Tefferi, Naseema Gangat

Blood (2024) 144 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2024-193120

Published: 2024

Journal Articles

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Blood (2024) 144 (Supplement 1): 3183.

https://doi.org/10.1182/blood-2024-202406

Published: 2024

Journal Articles

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Terra L. Lasho, Jenna A. Fernandez, Jeong-Heon Lee, Linh D. Pham, Huihuang Yan, Christy Finke, Abhishek A. Mangaonkar, Aref Al-Kali, Naseema Gangat, Joseph Collard, Claes Wahlestedt, Mrinal M. Patnaik, Moritz Binder

Blood (2024) 144 (Supplement 1): 3197.

https://doi.org/10.1182/blood-2024-204070

Published: 2024

Journal Articles

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Naseema Gangat, Giuseppe Gaetano Loscocco, Patricia Carey, Priyansh Faldu, Moazah Iftikhar, Masooma S Rana, Yamna Jadoon, Animesh D. Pardanani, Natasha Szuber, Alessandra Carobbio, Tiziano Barbui, Alessandro Maria Vannucchi, Ayalew Tefferi, Paola Guglielmelli

Blood (2024) 144 (Supplement 1): 3185.

https://doi.org/10.1182/blood-2024-204138

Published: 2024

Journal Articles

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

Mahlet Siraga, Maymona Abdelmagid, Moazah Iftikhar, Masooma S Rana, Kebede Begna, Kaaren K. Reichard, Rong He, Cinthya Zepeda Mendoza, Ronald S Go, Animesh D. Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2024) 144 (Supplement 1): 6625.

https://doi.org/10.1182/blood-2024-198840

Published: 2024

Journal Articles

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Talha Badar, Kashish J. Shah, Mobachir El Kettani, James M. Foran, Mohamed A. Kharfan-Dabaja, Hemant S. Murthy, Naseema Gangat, Aref Al-Kali, Mithun V Shah, Hassan B Alkhateeb, Antoine N. Saliba, William J. Hogan, Cecilia Y. Arana Yi, Lisa Sproat, Jeanne Palmer, Mark R. Litzow, Mrinal M. Patnaik

Blood (2024) 144 (Supplement 1): 1823.

https://doi.org/10.1182/blood-2024-203825

Published: 2024

NARROW

High-dose IV ascorbic acid therapy for patients with CCUS with TET2 mutations

Prevalence and Clinical Features of Non-Myeloid Neoplasms in Patients with DDX41 Mutant Germline Predisposition Syndrome

Molecular and Cytokine Correlates of Anemia Response to Treatment with DISC-0974 (An Anti-Hemojuvelin Antibody) in Non-Transfusion-Dependent Patients with Myelofibrosis

Polycythemia Vera Vs. JAK2 Mutated or Wild-Type Essential Thrombocythemia: Clinical and Molecular Comparisons and Long-Term Outcome Among 2,010 Patients

Comparative Analysis of Oligomonocytic CMML with Myelodysplastic and Myeloproliferative CMML Subtypes: A Study of 849 Molecularly-Annotated Patients

Outcome of Splenectomy in JAK2 Inhibitor Treated Patients with Myelofibrosis: A Mayo Clinic Experience in 34 Consecutive Cases

TP53 mutations and Complex Karyotype in Newly-Diagnosed Blast/Accelerated Phase MPN Are Associated with Ephemeral Response to Treatment with Venetoclax + HMA and Poor Survival

Revised International Working Group Risk Model for Survival in Polycythemia Vera

Homozygosity of the JAK2 46/1 or GGCC Haplotype Contributes to Phenotype and Outcome Diversity Among Patients with Polycythemia Vera

Monocytosis Is an Independent Risk Factor for Survival in Essential Thrombocythemia - a Revised Triple-a Prognostic Score (AAA+A) Based on Age and Absolute Monocyte, Neutrophil, and Lymphocyte Counts

Pacritinib Therapy for JAK2 Inhibitor-Naïve or -Experienced Patients with Myelofibrosis: Mayo Clinic Series of 60 Consecutive Patients Treated Outside of Clinical Trials

The Mutational Landscape of Polycythemia Vera and Its Phenotypic and Prognostic Correlates

TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance

A Phase 1b Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Myelofibrosis and Anemia

Cytogenetic Abnormalities in Polycythemia Vera: Phenotypic Correlates and Prognostic Relevance in 669 Informative Cases

Clinical Characteristics of Myeloproliferative Neoplasms in Patients with DDX41 MT Germline Predisposition Syndrome

Targeting Aberrant DLK1 Re-Expression in ASXL1 -Mutant Chronic Myelomonocytic Leukemia with BRD4 / p300-Directed Epigenetic Small Molecule Therapy

Thrombosis Risk Assessment in Polycythemia Vera (TRAP): A 4,636-Patient-Year Analysis of Arterial and Venous Thrombosis in Low-Risk Patients

Basophilia in Polycythemia Vera Is Associated with an Increased Risk of Leukemic and Myelofibrotic Transformation

Venetoclax in Combination with Hypomethylating Agent (HMA) Compared to HMA Alone Improves Response but Not Survival in TP53- mutated High-Risk Myelodysplastic Syndrome: Real-World Mayo Clinic Series

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only